Skip to main content
Belgian Biosafety Server
Menu
Search
Search
Main navigation
Home
Notification procedures
Notification procedures sub-navigation
Contained use GMOs/pathogens
Brussels-Capital
Flanders
Wallonia
Supporting tools
Scope legislation
Belgian classification for micro-organisms
Criteria for classification
Definitions of classes of biological risk
Methodology classification lists
International classifications
Criteria for GMM class of risk 1
Criteria for transgenic animals class of risk 1
Criteria transgenic plants class of risk 1
Risks of viral vectors
Risks of inserts
Risks of cell cultures
Guidelines for clinical laboratories
Animal cell cultures
Animal cell cultures (Annexes)
Flow cytometry
Flow cytometry (Annexes)
Ebola
Criteria for containment levels
Micro-organisms susceptibility to disinfectants
Micro-organisms susceptibility to disinfectants (Annexes)
Formaldehyde
Biosafety guidelines for SARS-CoV-2
Biosafety guidelines for the contained use of mpox virus
Emergency plans GMMs
Emergency plans - FAQ
Emergency plans - Glossary
Some figures
Clinical Trials GMOs
Supporting tools
Database
Some figures
Environmental release GMOs for R&D
Supporting tools
Database
Some figures
Commercialisation medicinal GMOs
Supporting tools
Some figures
Authorisations GMO-veterinary
Authorisations GMO-human
Commercialisation GMOs environment or food/feed
Supporting tools
Some figures
Dossier C/BE/96/01
Regulatory framework
Regulatory framework sub-navigation
EU framework
Contained use GMMs
Deliberat​e release GMOs
Decisions releases GMOs
GM Food/Feed
Medicinal GMOs
Worker's protection
Other regulations
Belgian framework
Cooperation agreement
Historical steps
Biosafety Council
SBB
Contained use GMOs/pathogens
Certification and exemptions
Historical perspective
Deliberate release GMOs
Historical background
Scientific assessment
GMO detection
NRL-GMO
Worker's protection
Thematic Areas
Thematic Areas sub-navigation
Assessment bio-risks
Biosecurity
Biosecurity - Annexes
Biosecurity - References
LAI
LAIs-References
LAIs-Cases
Genome editing
SBB opinion on CRISPR/Cas9
References
Polio eradication
Poliovirus - Definition
Polio eradication - References
Containment polio - History
Synthetic biology
Transport
Transport - Annexes
Historical Background
Historical Background sub-navigation
Biological risk classification
Recombinant DNA
GMO - From lab to field
​OECD activities
EU GMO Directives
EU GMO definition
FAQ
Events
Events sub-navigation
Upcoming Events
Past Events
Our events
MEACB 2017
About the SBB
About the SBB sub-navigation
Tasks and activities
Risk assessment
Scientific support
International
Networking activities of the SBB
Research
Communication
Publications
Contact Us
* NEW (02-04-2026) *
Search
Search
Language switcher
EN
FR
NL
Search the database for deliberate release of GM medicinal products
Displaying 1 - 3 of 3
Fulltext search
Apply
EU record number
Title
Company / Sponsor
Treated organism
Genetic modification
CYAD-N2L-101
An open-label, Phase I study to assess the safety of multiple doses of CYAD-101, administered after standard FOLFOX chemotherapy in patients with unresectable metastatic colorectal cancer (alloSHRINK-study-Standard cHemotherapy Regimen and Immunotherapy w
Celyad
Humans
NKG2D-chimeric antigen receptor, the truncated CD19 tag and the TIM8 molecule which interferes with the interaction between the natural TCR and endogenous CD3ζ
CYAD-N2T-006
An open-label, phase I study to assess the safety of NKR-2 treatment administrated concurrently with 5-azacytidine in tretment-naïve acute myeloid leukemia or myelodysplastic syndrome patients not candidates for intensive therapy (EPITHINK - EPIgenetic dr
Celyad
Humans
NKG2D-chimeric antigen receptor
Only notified under the "contained use" procedure. Dossier submitted on
25 April, 2018
.
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Kite Pharma
Humans
Chimeric antigen receptor against CD19
